Circulating progenitor cell collection: Experience from 275 leukaphereses in various malignancies and in healthy donors

Haematologica

Volumn 81, Issue 3, 1996, Pages 208-215

  Torretta, Lorella ^a   Perotti, Cesare ^a   Dornini, Gianluca ^a   Danova, Marco ^b   Locatelli, Franco ^a   Pedrazzoli, Paolo ^c   Preti, Pietro ^c   Da Prada, Gian Antonio ^c   Pavesi, Lorenzo ^c   Della Cuna, Gioacchino Robustelli ^c   Salvaneschi, Laura ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Ist di Med Int e Oncologia Medica

^c IRCCS   (Italy)

Author keywords

Blood cell transplantation; Circulating progenitor cells; High dose chemotherapy; Recombinant human granulocyte colony stimulating factor

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEFEROXAMINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; MITOXANTRONE; PREDNISONE; THIOTEPA; VINCRISTINE;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL SEPARATION; DONOR; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HUMAN; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MONONUCLEAR CELL; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; SOLID TUMOR; STEM CELL TRANSPLANTATION;

ADULT; CASE-CONTROL STUDIES; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKAPHERESIS; MALE; MIDDLE AGED; NEOPLASMS; REFERENCE VALUES;

EID: 0030326629     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. + positive haematopoietic cells: biology and clinical application. Blood Rev 1994; 8:113-24.
2. Reiffers J, Marit G, Vezon G, et al. Autologous blood stem cell grafting in hematological malignancies. Present status and future directions. Transfus Sci 1992; 13:399-405.
3. Kanz L, Brugger W, Mertelsmann R. Haematopoietic growth factors and peripheral blood stem cells as supportive agents in dose intensification. Eur J Cancer 1993; 29A(Suppl. 5): S23-S26.
4. Tarella C, Ferrero D, Bregni M, et al. Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamideand rhGM-CSF. Eur J Cancer 1991; 27:22-7.
5. Kotasek D, Shepherd KM, Sage RE, et al. Factors affecting blood stem cell collection following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transpl 1992; 9:11-7.
6. Teshima T, Harada M, Takamatsu Y, et al. Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting. Bone Marrow Transpl 1992; 10:215-20.
7. Indovina A, Majolino I, Buscemi F, et al. Engrafment kinetics and long-term stability of hematopoiesis following autografting of peripheral blood stem cells. Haematologica 1995; 80: 115-22.
8. Williams SF, Bitran JD, Richards JM, et al. Peripheral blood-derived stem cell collections for use in autologous transplantation after high dose chemotherapy: an alterantive approach. In: Gross S, Gee A, Worthington-White D, eds. Bone marrow purging and processing. New York: Wiley-Liss, 1990:461-9.
9. Ayash LJ, Wheeler C, Fairclough D et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13:2043-9.
10. Kessinger A, Bierman PJ, Vose JM, et al. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral blood stem cell transplantation for patients with relapsed Hodgkin's disease. Blood 1991; 77: 2322-5.
11. To LB, Haylock DN, Dyson PG, et al. A comparison between 4 g/sqm and 7 g/sqm cyclophosphamide for peripheral blood stem cell mobilization. Int J Cell Cloning 1992; Suppl 1: 33-4.
12. Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83:3787-94.
13. Zimmerman TM, Lee WJ, Bender JG, Mick R, Williams SF. Quantitative CD 34 analysis may be used to guide peripheral blood stem cell harvests. Bone Marrow Transpl 1995; 9: 439-44.
14. Carlo Stella C, Cazzola M, De Fabritiis P, et al. CD34-positive cells: biology and clinical relevance. Haematologica 1995; 80:367-87.
15. Schneider JG, Crown JP, Wasserheit C, et al. Factors affecting the mobilization of primitive and commited hematopoietic progenitors into the peripheral blood of cancer patients. Bone Marrow Transpl 1994; 14:877-84.
16. Dreger P, Suttorp M, Haferlach T, et al: G-CSF mobilized peripheral blood progenitor cells for allogeneic transplantation: Safety, kinetics of mobilization, and composition of the graft. Br J Haematol 1994; 87:609-13.
17. Siena S, Bregni M, Brando B, et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77:400-9.
18. Weaver CH, Bensinger WI, Appelbaum FR, et al. Phase 1 study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transpl 1994; 14:813-9.
19. Myers SE, Williams SF, Geller RB. Cyclophosphamide mobilization of peripheral blood stem cells for use in autologous transplantation after high dose chemotherapy: clinical results in patients with contaminated or hypocellular bone marrow. J Hematother 1992; 1:27-33.
20. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as onsolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11:1132-43.
21. Ravagnani F, Siena S, Bregni M, Sciorelli G, Gianni AM, Pellegris G. Large-scale collection of circulating haematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human GM-CSF. Eur J Cancer 1990; 26:562-4.
22. Gianni AM, Siena S, Bregni M, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; ii:580-5.
23. + cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens. Bone Marrow Transpl 1994; 13:479-85.
24. Venturini M, Del Mastro L, Melioli G, et al. Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony-stimulating factor for breast cancer therapy. Cancer 1994; 74:2300-6.
25. Demuynck H, Delforge M, Verhoef G, Zachee P, Vandenberghe P, Boogaerts M. Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF. Br J Haematol 1995; 90:384-92.
26. Majolino I, Marcenò R, Buscemi F, et al. Mobilization of circulating progenitor cells in multiple myeloma during VCAD therapy with or without rhG-CSF. Haematologica 1995; 80:108-14.
27. Bensinger WI, Longin K, Appelbaum F, et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony-stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87:825-31.
28. + cell estimation in peripheral blood for autografting in patients with cancer. In: Vunder F, Sovalat H, Henon PR, Serke S, eds. Haematopoietic stem cells. The Mulhouse manual. Dayton: Alphamed Press, 1994:23-30.
29. + blood cells predicts the colony-forming capacity of leukapheresis products in children. Bone Marrow Transpl 1995; 15:25-31.
30. Bennet ST, Johnson NL, Lasky LC. Quality assurance and standards in hematopoietic progenitor processing. J Clin Apheres 1992; 7:138-44.
31. Goldman J. Peripheral blood stem cells for allografting. Blood 1995; 85:1413-5.
32. Russel NH, Hunter AE. Peripheral blood stem cells for allogeneic transplantation. Bone Marrow Transpl 1994; 13:353-5.
33. Russel JA, Luider J, Weaver M, et al. Collection of progenitor cells for allogeneic transplantation from peripheral blood of normal donors. Bone Marrow Transpl 1995; 15:111-5.
34. Majolino I, Aversa F, Bacigalupo A, Bandini G, Arcese W, Reali G. Allogeneic transplants of rhG-CSF mobilized peripheral blood stem cells (PBSC) from normal donors. Haematologica 1995; 80:40-3.
35. Locatelli F, Pedrazzoli P. Recombinant human G-CSF: how wide is the field of clinical applicability? Haematologica 1995; 80:199-205.
36. Goldberg SL, Mangan KF, Klumpp TR, et al. Complications of peripheral blood stem cell harvesting: review of 554 PBSC leukaphereses. J Hematother 1995; 4:85-90.
37. Haire WD, Stephens LC, Kotulak GD, Schmmit-Pokorny K, Kessinger A. Double-lumen inferior vena cava catheters for peripheral stem cell apheresis and transplantation. Transfus Sci 1995; 16:79-84.
38. Lansdorp PM. Developmental changes in the function of hematopoietic stem cells. Exp Hematol 1995; 23:187-91.
39. Comenzo RL, Berkman EM. Hematopoietic stem and progenitor cells from blood: emerging uses for new component for transfusion. Transfusion 1995; 35:335-45.
40. Bregni M, Magni M, Siena S, Di Nicola M, Bonadonna G, Gianni AM. Human peripheral blood hematopoietic progenitors are optimal targets of retroviral mediated gene transfer. Blood 1992; 80:1418-22.
41. Snyder EL. Hematopoietic cell therapy and transfusion medicine-carpe diem? Transfusion 1995; 35:371-3.